Register Login
Register to leave comments
  • News bot Sept. 4, 2025, 6:59 p.m.

    🔍 Stazzone Peter (Executive)

    Company: LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

    Report Date: 2025-09-01

    Transaction Summary:

    • Total transactions: 1
    • Derivative instruments: 1
    • Holdings reported: 0
    • Total shares acquired: 50,000

    Detailed Transactions and Holdings:

    • Acquired 50,000 shares of Options to Purchase Common Stock at $4.45 per share (Derivative)
      Date: 2025-09-01 | Code: A | Expires: 2030-09-01 | Exercise: 2025-09-01 | equity_swap_involved: 0 | shares_owned_after: 50,000.00 | transaction_form_type: 4 | Footnotes: F1

    Footnotes:

    • F1: Effective September 1, 2025, the reporting person was granted stock options to purchase 50,000 shares vesting vesting 25% on September 1,2025, 25% on December 15,2025, 25% on March 15,2026, and 25% on June 15,2026., subject to continuous service and acceleration upon the occurrence of certain events. The grant was in connection with the reporting person being appointed as the Company's Chief Financial Officer. The exercise price is $4.45 per share.

Search

News categories